Flu vaccine induces short-lived bone marrow plasma cells, limiting vaccination longevity

August 13, 2020

Influenza-specific bone marrow plasma cells - responsible for maintaining the level of protective antibodies following a flu shot - are short-lived, and decline to their pre-vaccination levels within a year, researchers report. While the findings help explain the lackluster persistence of the antibody response often observed from the annual influenza vaccination, the new study offers insight into how the longevity of the next generation of vaccines could be enhanced. Ideally, a successful vaccine stimulates the body's adaptive immunity to produce pathogen-specific antibodies, which imbues an individual with long-lasting protection against future infection. For many vaccines, the levels of a new antibody peak in the months following vaccination and decline to a "plateau level" that can be maintained for decades. However, this is not the case for common influenza vaccines; antibody levels and protective immunity decline rapidly after each seasonal vaccination. In a novel clinical study that spanned eight flu seasons and 53 participants, Carl Davis and colleagues tracked the production and maintenance of influenza-specific bone marrow plasma cells (BMPCs) following flu vaccination. Davis et al. collected bone marrow samples pre-vaccination, one month post-vaccination and one year post-vaccination, which allowed the authors to assess the long-term vaccine response and antibody maintenance. For some individuals, they assessed this for several seasonal vaccination cycles. The results showed that vaccination did spur the generation of influenza-specific BMPC, which were present in increased numbers a month following immunization. However, most of the newly formed BMPC were quickly lost, returning to pre-vaccination levels within a year. Despite this, Davis et al. show that a small number did persist more than a year, suggesting that the longevity of flu vaccines can be improved.
-end-


American Association for the Advancement of Science

Related Influenza Articles from Brightsurf:

Predicting influenza epidemics
Researchers at Linköping University, Sweden, have developed a unique method to predict influenza epidemics by combining several sources of data.

Common cold combats influenza
As the flu season approaches, a strained public health system may have a surprising ally -- the common cold virus.

Scent-sensing cells have a better way to fight influenza
Smell receptors that line the nose get hit by Influenza B just like other cells, but they are able to clear the infection without dying.

New antivirals for influenza and Zika
Leuven researchers have deployed synthetic amyloids to trigger protein misfolding as a strategy to combat the influenza A and Zika virus.

Assessment of deaths from COVID-19, seasonal influenza
Publicly available data were used to analyze the number of deaths from seasonal influenza deaths compared with deaths from COVID-19.

Obesity promotes virulence of influenza
Obesity promotes the virulence of the influenza virus, according to a study conducted in mice published in mBio, an open-access journal of the American Society for Microbiology.

Influenza: combating bacterial superinfection with the help of the microbiota
Frenc researchers and from Brazilian (Belo Horizonte), Scottish (Glasgow) and Danish (Copenhagen) laboratories have shown for the first time in mice that perturbation of the gut microbiota caused by the influenza virus favours secondary bacterial superinfection.

Chemists unveil the structure of an influenza B protein
MIT chemists have discovered the structure of an influenza B protein called BM2, a finding that could help researchers design drugs that block the protein and help prevent the virus from spreading.

How proteins help influenza A bind and slice its way to cells
Researchers have provided new insight on how two proteins help influenza A virus particles fight their way to human cells.

Eating elderberries can help minimize influenza symptoms
Conducted by Professor Fariba Deghani, Dr. Golnoosh Torabian and Dr.

Read More: Influenza News and Influenza Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.